Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study

Circulation

Volumn 110, Issue 17, 2004, Pages 2687-2693

  Sattar, Naveed ^a   Williams, Ken ^b   Sniderman, Allan D ^c   D'Agostino Jr , Ralph ^d   Haffner, Steven M ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Glucose; Prevention; Risk factors

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

ADULT; AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDIES; RISK FACTORS;

EID: 7544238820     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000145660.60487.94     Document Type: Article

References (32)

1. Sniderman AD, Furberg CD, Keech A, et al. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy. Lancet. 2003;361:777-780.
2. Williams K, Sniderman AD, Sattar N, et al. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108:2312-2316.
3. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
5. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
6. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
7. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136-141.
8. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
9. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153-3159.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;16:356-359.
11. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-1419.
12. Sniderman AD, St Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91:1173-1177.
13. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design, and recruitment results. Ann Epidemiol. 1995;5:464-472.
14. Festa A, D'Agostino R Jr, Tracy RP, et al. The Insulin Resistance Atherosclerosis Study: elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51:1131-1137.
15. Bachorik PS, Lovejoy KL, Carroll MD, et al. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 1997;43:2364-2378.
16. Connelly PW, Poapst M, Davignon J, et al. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan: Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15:409-418.
17. Contois JH, McNamara JR, Lammi-Keefe CJ, et al. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem. 1996;42:515-523.
18. Steiger JH. Tests for comparing elements of a correlation matrix. Psychological Bull. 1980;87:245-251.
19. Brunzell JD, Schrott HG, Motulsky AG, et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metab Clin Expl. 1976;25:313-320.
20. Sniderman AD, Wolfson C, Teng B, et al. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 1982;97:833-839.
21. Kukita H, Hamada M, Hiwada K, et al. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis. 1985;55:143-149.
22. Durrington PN, Hunt L, Ishola M, et al. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J. 1986;56:206-212.
23. Barbir M, Wile D, Trayner I, et al. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J. 1988;60:397-403.
24. Lamarche B, Despres JP, Moorjani S, et al Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cordial. 1995;75:1189-1195.
25. Talmud PJ, Hawe E, Miller GJ, et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22:1918-1923.
26. Keulen ET, Kruijshoop M, Schaper NC, et al. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol. 2002;22:283-288.
27. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
28. Genest J, Frolich J, Fodor G, et al. Recommendation for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J. 2003 28;169:921-924.
29. Collins-Nakai RL, Dagenais GR. The role of the cardiovascular specialist in the prevention of cardiovascular diseases: executive summary. Can J Cardiol. 1999;15(suppl G):7G-16G.
30. Leiter LA, Manon J, Chye T, et al. Macrovascular complications, dyslipidemia and hypertension. Can J Diabetes. 2003;27(suppl 20):S58-S65.
31. van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20:2408-2413.
32. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.